Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Buprenorphine buccal - BioDelivery Sciences International

Drug Profile

Buprenorphine buccal - BioDelivery Sciences International

Alternative Names: BELBUCA; BEMA Buprenorphine; BEMA® LA; BEMA® Long Acting; Buprenorphine long acting; Buprenorphine transmucosal; EN 3409

Latest Information Update: 14 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioDelivery Sciences International
  • Developer BioDelivery Sciences International; Purdue Biopharma
  • Class Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Pain

Most Recent Events

  • 23 Jul 2019 BioDelivery Sciences International initiates a phase I trial in Pain (In volunteers) in USA (Buccal, Film) (NCT03996694)
  • 25 Jun 2019 BioDelivery Sciences International and PRA Health Sciences plan a phase I trial to compare the ventilatory response to Hypercapnia after administration of buprenorphine buccal, oxycodone HCl and placebo in recreational opioid users (In volunteers) in USA (Buccal, Film), in July 2019 (NCT03996694)
  • 07 Feb 2018 BioDelivery Sciences settles litigation against Teva Pharmaceuticals over ANDA submission in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top